The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs

dc.contributor.authorAltan, Feray
dc.contributor.authorIpek, Duygu Neval Sayin
dc.contributor.authorCorum, Orhan
dc.contributor.authorAlp, Simten Yesilmen
dc.contributor.authorIpek, Polat
dc.contributor.authorUney, Kamil
dc.date.accessioned2024-04-24T16:02:23Z
dc.date.available2024-04-24T16:02:23Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe study aimed to define the effects of M. haemolytica and a single oral dose of albendazole on the single-dose pharmacokinetics of marbofloxacin in lambs. The pharmacokinetic-pharmacodynamic integration of marbofloxacin was applied to describe a 3 mg/kg intramuscular dose in lambs. The 6 healthy and 12 naturally infected with M. haemolytica lambs (Akkaraman, males weighing 10-15 kg and aged 2-3 months) were used in this study. In the marbofloxacin group, 6 healthy lambs received marbofloxacin. In the albendazole group after 2 weeks washout period, the same animals received marbofloxacin on 1 h after albendazole. In the diseased marbofloxacin group, 6 lambs naturally infected with M. haemolytica received marbofloxacin. In the diseased albendazole group, 6 lambs naturally infected with M. haemolytica received marbofloxacin on 1 h after albendazole. The marbofloxacin and albendazole were administered each as a single dose of 3 mg/kg intramuscular and 7.5 mg/kg oral, respectively, in the respective groups. Plasma concentration of marbofloxacin was measured with HPLC-UV and pharmacokinetic parameters were analyzed by non-compartmental model. Albendazole did not change the pharmacokinetic profiles of marbofloxacin in healthy and diseased lambs. However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC(0-24)/MIC90 ratio was not found to be higher than 125, but C-max/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 mu g/mL in all groups. The marbofloxacin dose described in this study may not be effective for the treatment of infections due to M. haemolytica in lambs, with MIC <= 0.25 mu g/mL.en_US
dc.identifier.doi10.1007/s11250-019-01980-5
dc.identifier.endpage2610en_US
dc.identifier.issn0049-4747
dc.identifier.issn1573-7438
dc.identifier.issue8en_US
dc.identifier.pmid31230255
dc.identifier.scopus2-s2.0-85068128991
dc.identifier.scopusqualityQ2
dc.identifier.startpage2603en_US
dc.identifier.urihttps://doi.org/10.1007/s11250-019-01980-5
dc.identifier.urihttps://hdl.handle.net/11468/14773
dc.identifier.volume51en_US
dc.identifier.wosWOS:000494799400057
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofTropical Animal Health and Production
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlbendazoleen_US
dc.subjectLamben_US
dc.subjectMannheimia Haemolyticaen_US
dc.subjectMarbofloxacinen_US
dc.subjectPharmacokineticsen_US
dc.titleThe effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambsen_US
dc.titleThe effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs
dc.typeArticleen_US

Dosyalar